MedTrace Logo

Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease

NCT03788252 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-12-17

No results posted yet for this study

Summary

This study is to assess the effect of 48 weeks administration of Renamezin capsule on prevention of sarcopenia in pre-dialysis patients with chronic kidney disease.

Conditions

  • Chronic Kidney Diseases

Interventions

DRUG

Renamezin

7 capsules once, three times a day, for 48 weeks

Sponsors & Collaborators

  • Gumi Cha Medical Center

    lead OTHER

Principal Investigators

  • Jun Chul Kim, MD, PhD · CHA Gumi Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-23
Primary Completion
2020-07-14
Completion
2020-07-14

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03788252 on ClinicalTrials.gov